Anzeige
Mehr »
Sonntag, 05.07.2026 - Börsentäglich über 12.000 News
Milliardenkonkurrenten im Visier: Dieser KI-Wert gewinnt namhafte Großkunden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PGFW | ISIN: CNE100003F01 | Ticker-Symbol: CJH
Tradegate
03.07.26 | 16:00
2,760 Euro
+1,47 % +0,040
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
CANSINO BIOLOGICS INC Chart 1 Jahr
5-Tage-Chart
CANSINO BIOLOGICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,7002,72004.07.
2,6602,76003.07.

Aktuelle News zur CANSINO BIOLOGICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoCanSino Biologics Inc: CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Further Expanding International Presence in South America392HONG KONG, June 29, 2026 - (ACN Newswire) - On June 25, CanSino Biologics Inc. (SSE: 688185, HKEX: 06185) announced that the Company's ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197)...
► Artikel lesen
25.06.CANSINOBIO MCV4 Obtains Registration Certificate in Argentina3
25.06.CANSINOBIO (06185): VOLUNTARY ANNOUNCEMENT - MCV4 OBTAINS DRUG REGISTRATION CERTIFICATE IN ARGENTINA-
10.06.CANSINOBIO (06185): ARTICLES OF ASSOCIATION1
10.06.CANSINOBIO (06185): POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION-
CANSINO BIOLOGICS Aktie jetzt für 0€ handeln
26.05.CANSINOBIO (06185): VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE I/II CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR PCV243
19.05.CANSINOBIO (06185): FORM OF PROXY FOR USE AT THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, JUNE 10, 202612
19.05.CANSINOBIO (06185): NOTICE OF 2025 ANNUAL GENERAL MEETING14
19.05.CANSINOBIO (06185): 2025 AGM CIRCULAR-
11.05.CANSINOBIO (06185): VOLUNTARY ANNOUNCEMENT - THE CENTER FOR DRUG EVALUATION, NMPA GRANTED PRIORITY REVIEW STATUS TO NDA FOR TD5CP ADOLESCENT AND ADULT3
28.04.CanSino Biologics Inc: CanSinoBIO Delivers Q1 Revenue Growth Amid Accelerating International Expansion592HONG KONG, Apr 28, 2026 - (ACN Newswire) - CanSino Biologics Inc. (688185.SH/06185.HK) released its first-quarter 2026 results, reflecting a positive operational momentum. Revenue for the quarter totaled...
► Artikel lesen
28.04.CANSINOBIO (06185): PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE RULES OF PROCEDURES1
28.04.CANSINOBIO (06185): FIRST QUARTERLY REPORT FOR THE THREE MONTHS ENDED MARCH 31, 20265
22.04.CANSINOBIO (06185): LETTER TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS ...2
22.04.CANSINOBIO (06185): LETTER TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS ...-
22.04.CANSINOBIO (06185): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) & SUSTAINABILITY REPORT-
22.04.CANSINOBIO (06185): 2025 ANNUAL REPORT1
16.04.CANSINOBIO (06185): NOTICE OF BOARD MEETING1
31.03.CanSino Biologics Inc: CanSinoBIO: From Profit Turnaround to Value Realization as an Innovative Vaccine Leader688HONG KONG, Mar 31, 2026 - (ACN Newswire) - HONG KONG, Mar 31, 2026 - (ACN Newswire) - China's 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry,...
► Artikel lesen
30.03.CANSINOBIO (06185): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025-
Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1